Efficacy and Safety of Flow-Directed Pulmonary Artery Catheter Thrombolysis for Treatment of Submassive Pulmonary Embolism
|
|
- Dominic Golden
- 6 years ago
- Views:
Transcription
1 Vascular and Interventional Radiology Original Research Gaba et al. Catheter Thrombolysis of Submassive PE Vascular and Interventional Radiology Original Research Ron C. Gaba 1 Madhu S. Gundavaram 2 Ahmad Parvinian 1 M. Grace Knuttinen 1 Jeet Minocha 1 Charles A. Owens 1 James T. Bui 1 Gaba RC, Gundavaram MS, Parvinian A, et al. Keywords: catheter-directed thrombolysis, efficacy, pulmonary embolism (PE), safety, submassive DOI: /AJR Received June 12, 2013; accepted after revision October 10, Presented at the 2013 annual meeting of the American Thoracic Society, Philadelphia, PA. 1 Department of Radiology, Division of Interventional Radiology, University of Illinois Hospital and Health Sciences System, 1740 W Taylor St, MC 931, Chicago, IL Address correspondence to R. C. Gaba (rgaba@uic.edu). 2 Department of Medicine, Division of Pulmonary, Critical Care, Sleep, and Allergy Medicine, University of Illinois Hospital and Health Sciences System, Chicago, IL. AJR 2014; 202: X/14/ American Roentgen Ray Society Efficacy and Safety of Flow-Directed Pulmonary Artery Catheter Thrombolysis for Treatment of Submassive Pulmonary Embolism OBJECTIVE. The purpose of this study was to assess the efficacy and safety of flow-directed catheter thrombolysis for treatment of submassive pulmonary embolism (PE). MATERIALS AND METHODS. In this single-institution retrospective study, 19 patients (nine men and 10 women; mean age [± SD], 54 ± 13 years) with submassive PE underwent catheter-directed thrombolysis between 2009 and Presenting symptoms included dyspnea in 18 of 19 (95%) cases. Submassive PE was diagnosed by pulmonary CT arteriography and right ventricular strain. PE was bilateral in 17 of 19 (89%) and unilateral in two of 19 (11%) cases. Thrombolysis was performed via a pulmonary artery (PA) catheter infusing mg alteplase per hour and was continued to complete or near complete clot dissolution with reduction in PA pressure. IV systemic heparin was administered. Measured outcomes included procedural success, PA pressure reduction, clinical success, survival, and adverse events. RESULTS. Procedural success, defined as successful PA catheter placement, fibrinolytic agent delivery, PA pressure reduction, and achievement of complete or near complete clot dissolution, was achieved in 18 of 19 (95%) cases. Thrombolysis required 57 ± 31 mg of alteplase administered over 89 ± 32 hours. Initial and final PA pressures were 30 ± 10 mm Hg and 20 ± 8 mm Hg (p < 0.001). All 18 (100%) technically successful cases achieved clinical success because all patients experienced symptomatic improvement. Eighteen of 19 (95%) patients survived to hospital discharge; 18 of 19 (95%) and 15 of 16 (94%) patients had documented 1-month and 3-month survival. One fatal case of intracranial hemorrhage was attributed to supratherapeutic anticoagulation because normal fibrinogen levels did not suggest remote fibrinolysis; procedural success was not achieved in this case because of early thrombolysis termination. No other complications were encountered. CONCLUSION. Among a small patient cohort, flow-directed catheter thrombolysis with alteplase effectively dissolved submassive PE and reduced PA pressure. Postprocedure short-term survival was high, and patients undergoing thrombolysis required close observation for bleeding events. P ulmonary embolism (PE) is a deadly disease that results in significant morbidity and mortality in the United States; up to 600,000 cases of PE are diagnosed annually and yearly deaths approximate 50, ,000 nationwide [1 4]. Massive and submassive PE which are PE subtypes associated with right ventricular (RV) dysfunction with or without systemic arterial hypotension, cardiogenic shock, or cardiac arrest are particularly deadly; 30-day mortality rates for these PE varieties may approximate 60% and 20%, respectively [5]. Although systemic anticoagulation can reduce overall PE mortality, this therapy neither dissolves existing clot nor prevents thrombus propaga- tion. Therefore, the American College of Chest Physicians (ACCP) and American Heart Association (AHA) recommend consideration of fibrinolytic therapy for massive acute PE [6, 7]. IV administration of fibrinolytic agents offers ease of delivery, but the high dose and uncontrolled distribution with systemic or remote lytic effects may complicate this approach and contribute to a major hemorrhage rate approximating 10% [7]; however, higher [5, 8] and lower rates have been reported [9]. In contrast, targeted catheter-based fibrinolytic agent delivery for treatment of massive PE has been associated with complication rates under 2.5% as well as 86.5% efficacy measured by stabiliza- AJR:202, June
2 Gaba et al. tion of hemodynamics, resolution of hypoxia, and survival to hospital discharge [10]. Although such advanced fibrinolytic therapy can thus be lifesaving in the setting of massive PE, its use remains unverified in patients with submassive PE [11], and practical application may be limited to those patients judged to have clinical evidence for an adverse prognosis [7]. With this in mind, this study was undertaken to assess the efficacy and safety of flow-directed catheter thrombolysis, or targeted clot dissolution, performed with fibrinolytic agent infusion into the pulmonary artery (PA) proximal to the embolus for treatment of submassive PE. Materials and Methods This retrospective study was in compliance with HIPAA, and the institutional review board at our institution granted approval with waiver of consent for inclusion in the study. All patients provided written informed consent for catheter-directed thrombolysis procedures, which were performed for the medical indication of PE fibrinolysis. Clinical Setting and Study Design Between September 2009 and May 2013, 19 consecutive patients with large clot burden and physiologic changes of submassive PE who underwent catheter-directed thrombolysis at a single tertiary care academic university hospital in a large metropolitan area were identified via medical record review and selected for retrospective study. Submassive PE was defined as PE associated with RV dysfunction without systemic arterial hypotension, cardiogenic shock, or cardiac arrest. Indications for PE thrombolysis included imaging confirmation of thrombus within the main or lobar pulmonary arteries; RV strain; and clinical symptoms such as dyspnea, chest pain, syncope, or dizziness. Submassive PE was diagnosed by pulmonary CT arteriography in 19 patients by the use of RV to left ventricular (LV) diameter ratio [12] and defined by RV strain on echocardiography in 17 patients. Submassive PE was evidenced by RV hypokinesis (n = 6), dilatation (n = 11), flattening of the interventricular septum (n = 7), and tricuspid regurgitation (n = 17) [13]. An intensive care physician evaluated all patients, and the decision to pursue catheter-directed fibrinolysis was determined by consensus discussion between critical care and interventional radiology physicians. Standard contraindications to thrombolytic agent administration [14] were considered in patient selection, and none of the patients in the current cohort had such contraindications. Catheter-Directed Thrombolysis Technique Catheter-directed thrombolysis was performed in the interventional radiology suite using IV moderate sedation anesthesia. For these procedures, patients were prepared and draped in standard sterile fashion while supine on the angiographic procedure table. Routine single-wall puncture venous access was gained via the right or left common femoral vein using direct sonographic guidance and a 21-gauge needle (Micropuncture Introducer Set, Cook Medical). Vascular access was dilated to accept an 8-French vascular sheath (Pinnacle, Terumo). A 7-French multisidehole pigtail catheter (APC, Cook Medical) was then advanced into the main pulmonary trunk. The APC catheter, or Van Aman pulmonary pigtail with APC tip configuration (a modification of the Grollman pulmonary pigtail), is a 100-cmlong inch internal diameter multisidehole (12 total) catheter with a 90 curve of its distal 5 cm as well as a distal pigtail with an end hole. Mean PA pressure was then recorded; right atrial and RV pressures were not measured. From the main pulmonary trunk, digital subtraction pulmonary arteriography was performed with iohexol (Omnipaque 300, GE Healthcare) injection at a flow rate of ml/s for a total injection volume of ml; flow rates were selected at the discretion of the primary operating interventional radiology on the basis of perceived PA flow velocity on hand injections of contrast material (notably, injection at a reduced flow rate is preferable in the presence of pulmonary hypertension and RV dysfunction associated with submassive PE so as not to provoke right heart failure). Catheter-directed thrombolysis using the flowdirected technique, which is a form of pharmacologic thrombolysis in which the infusion is administered through a catheter positioned in the PA proximal to the location of PA thrombus, was then pursued. The catheter was positioned in the PA with the greater clot burden (preprocedure pulmonary CT arteriography can assist in this regard) immediately proximal to the location of PA thrombus, with administration of 0.5 mg (n = 14) or 1.0 mg (n = 5) alteplase (Activase, Genentech) per hour (infusion rate of 60 ml/h of 8 mg alteplase/1000 ml saline preparation, 120 ml/h of 4 mg alteplase/1000 ml saline preparation, or 120 ml/h of 8 mg alteplase/1000 ml saline preparation); these preparations and infusion rates are the same as those used for peripheral catheter-directed thrombolysis at our institution. Alteplase dosing was at the discretion of the operating interventional radiology physician; the term low dose refers to PA infusion of mg alteplase per hour, whereas high dose denotes IV infusion with 100 mg alteplase administered over 2 hours. Systemic IV heparin was also administered to prevent thrombus propagation and was titrated to achieve a partial thromboplastin time (PTT) of seconds; subtherapeutic doses of heparin have been deemed acceptable when used in combination with thrombolytic therapy [15]. Patients were continuously monitored in an ICU setting during the entirety of thrombolytic therapy. Laboratory values, including hematologic parameters such as CBC, coagulation profile including prothrombin time (PT) and PTT, and fibrinogen levels, were monitored every 4 6 hours. Although the clinical progress of catheter-directed thrombolysis may be assessed by evaluating patient hemodynamic status, oxygen saturation, and pulmonary artery pressure, daily pulmonary arteriography was performed in the interventional radiology suite in accordance with our institutional protocol to monitor the progress of thrombolytic therapy and to ensure catheter positional stability and enable catheter repositioning as needed. Catheter repositioning into the contralateral PA was pursued when complete or near complete clot dissolution was achieved in the initially treated PA. This methodology was used with the intent of minimizing vascular access punctures and maintaining a low thrombolytic agent dose with a single rather than dual infusion. Moreover, prior in vitro and in vivo studies have shown contralateral flow of thrombolytic agent administered into a large embolus-containing PA [16], theoretically allowing some simultaneous contralateral clot dissolution. Thrombolysis was continued until PA pressure reduction and concomitant resolution of patient symptoms were achieved; complete or near complete clot dissolution in both PAs was considered a secondary termination endpoint. No mechanical clot disruption techniques were pursued in any case. After completion of thrombolytic therapy, the PA catheter was removed over a guidewire under fluoroscopic guidance, the vascular access sheath was removed, and hemostasis was achieved at the common femoral venotomy site with manual compression. Of note, patients were generally maintained on a 6-month course of systemic anticoagulation after completion of catheter-directed thrombolysis. Measured Outcomes Electronic medical records were reviewed to obtain patient demographic information, risk factors for venous thromboembolism (VTE), patient comorbidities, presenting signs and symptoms, procedure data, clinical outcomes including symptomatic improvement or resolution after treatment, ICU length of stay, hospital length of stay, survival to discharge, 30-day survival, and 1356 AJR:202, June 2014
3 Catheter Thrombolysis of Submassive PE 90-day survival. Patient mortality was confirmed using the United States Social Security Death Index. Data were collected for each patient using a standardized data collection form. Measured study outcomes included procedure technical success, procedural success, clinical success, survival to hospital discharge, and C A 30- and 90-day survival. Technical success was defined as successful PA catheter placement and effective fibrinolytic agent delivery [17]. Procedural success was defined as technical success plus achievement of the intended interventional therapeutic goal, in this case PA pressure reduction and complete ( 90% clearance) or near complete (70 90% clearance) clot dissolution [2]. Clot dissolution was visually estimated on a per-case basis via analysis of initial and final pulmonary arteriograms. Incremental per day clot dissolution rates were not reported because visual estimation of small changes in clot size was thought to be subject to significant error that may introduce Fig year-old man with acute onset of dyspnea associated with oxygen saturation of 87% on room air. A, Axial contrast-enhanced chest CT image shows large bilateral pulmonary embolisms (PEs) (arrowheads). B and C, Right (B) and left (C) pulmonary arteriograms (10-mL/s iodinated contrast medium injection) show significant right-sided PE (arrowheads, B) as large filling defect with poor flow in lower lobe pulmonary artery (PA) branch (arrow, B) and reduced parenchymal perfusion as well as multiple emboli in left-sided branches (arrowheads, C). D, Pulmonary arteriogram (15 ml/s iodinated contrast medium injection) obtained after 96 hours of catheter-directed thrombolysis to right pulmonary artery using 0.5 mg of alteplase per hour displays greater than 90% clot dissolution, with marked progressive reduction in PE size (arrowheads) and only minimal residual PE as well as significant improvement in PA perfusion (arrow). E, Pulmonary arteriogram shows left-sided PE similarly resolved, although without direct alteplase infusion. PA pressure decreased from mean of 52 to 18 mm Hg, and oxygen saturation improved to 96% on room air. D B E AJR:202, June
4 Gaba et al. inaccuracy into the clot dissolution outcome measure. Of note, although the diagnosis of submassive PE is not based on embolus burden, clearance of thrombus was considered to be an appropriate and valuable therapeutic endpoint in conjunction with PA pressure reduction in this study because the intent of thrombolytic therapy was to pursue active thrombus clearance to bring about PA reduction. Clinical success was defined by improvement in patient clinical signs and symptoms as well as adverse events, graded according to the Society of Interventional Radiology classification of complications [17]. Statistical Analysis Descriptive statistics were used to check for erroneous entries, assess for normalcy of the data, and characterize demographic features of the study population. Comparisons for continuous normally distributed variables were performed by the unpaired or paired samples Student t test. Statistical analysis was performed using a commercially available software package (SPSS version 18), and p values 0.05 were considered statistically significant. Results Patient Cohort and Pulmonary Embolism Characteristics The study cohort consisted of 19 patients, including nine men and 10 women with a mean age ± SD of 54 ± 13 years (range, years). VTE risk factors included obesity (11/19, 58%), hypertension (10/19, 53%), immobility (3/19, 16%), malignancy (3/19, 16%), and smoking (2/19, 11%). Mean body mass index was 36.3 ± 12.6 kg/m 2 (range, kg/m 2 ). Presenting symptoms included new onset of dyspnea (18/19, 95%), chest pain (6/19, 32%), syncope (4/19, 21%), or dizziness (2/19, 11%). PE location was saddle or bilateral in 17 of 19 (89%) cases and unilateral in two of 19 (11%) cases. CT showed a mean RV to LV ratio of 1.5 ± 0.3 (range, ). Twelve of 19 (63%) patients had lower extremity deep venous thrombosis on presentation diagnosed by lower extremity Duplex sonography. Catheter-Directed Thrombolysis Procedures The time from initial patient presentation to medical attention to initiation of catheter-directed thrombolysis was 30 ± 28 hours (range, 4 96 hours). Thrombolysis required a mean of 57 ± 31 mg (range, mg) of alteplase administered over a mean of 89 ± 32 hours (range, hours). There was no statistically significant difference in thrombolysis procedure length when alteplase was dosed at 0.5 mg per hour compared with 1.0 mg per hour (91 vs 82 hours, p = 0.517). Systemic fibrinogen levels averaged 480 ± 167 mg/dl (range, mg/dl) during treatment. No patients had fibrinogen levels that dropped below 200 mg/dl. Technical success was achieved in all 19 (100%) cases. Among these patients, 18 (95%) achieved procedural success (Fig. 1), in whom complete thrombolysis was achieved in 11 (61%) patients and near-complete thrombolysis was achieved in seven (39%) patients. Catheter repositioning to the contralateral PA was necessary to achieve contralateral clot dissolution in four cases. Contralateral thrombus dissolution without catheter repositioning was seen in 11 cases. A statistically significant decrease in PA pressure was detected; mean initial and final PA pressures were 30 ± 10 mm Hg (range, mm Hg) and 20 ± 8 mm Hg (range, 8 37 mm Hg), respectively (p < 0.001). Mean PA pressure reduction was 10 ± 9 mm Hg (minimum reduction, 1 mm Hg, maximum reduction, 34 mm Hg). Eight of 19 (42%) patients had complete normalization of PA pressure (mean 18 mm Hg). Of note, no patients experienced a catheter-induced cardiac arrhythmia during the course of thrombolytic agent infusion. Clinical Outcomes Eighteen of the 18 (100%) technically successful cases achieved clinical success; all patients experienced symptomatic improvement with resolution of their initially presenting symptom on completion of catheterdirected thrombolysis. Of these patients, 17 (94%) had symptomatic improvement before resolution of thrombus (mean time to symptomatic improvement was 49 hours and mean PA pressure at the time of symptomatic improvement was 24 mm Hg). Mean length of ICU stay (inclusive of time before thrombolysis initiation) was 4.7 ± 2.3 days (range, 2 10 days), and mean length of hospital stay was 10.5 ± 7.8 days (range, 2 34 days). Eighteen of 19 (95%) patients survived to hospital discharge. The 30-day survival rate was 95% (18/19) and 90-day survival was 94% (15/16) (three patients had not reached 90 days postprocedure at the time of this writing). There were no minor or major complications among surviving patients. One patient (5%) developed cerebral hemorrhage 24 hours after catheter-directed thrombolysis initiation and subsequently died because of intracranial bleeding. However, systemic anticoagulation in this patient was complicated by labile PTT with elevation to greater than 200 seconds for approximately 2 hours. Fibrinogen levels in this patient ranged from 386 to 486 mg/dl during thrombolysis, indicating no systemic alteplase thrombolytic effect. Supratherapeutic anticoagulation was thus determined to be the cause of the patient s hemorrhagic event. Discussion The application of thrombolytic therapy for treatment of submassive PE is currently considered controversial [18, 19]. Data for the use of fibrinolytic agents in this setting are sparse despite the considerable shortterm mortality associated with submassive PE [5], poor prognosis of PE patients with RV dysfunction and PA pressure elevation [20], and significant incidence of chronic pulmonary hypertension among survivors of submassive PE events [21]. In the 256-patient prospective randomized Management Strategies and Prognosis of Pulmonary Embolism Trial-3 reported by Konstantinides et al. [9] in 2002, a statistically significant decrease in the rate of in-hospital death or clinical deterioration requiring an escalation of treatment (11.0% vs 24.6%) was observed in patients with acute submassive PE treated with systemic anticoagulation plus bolus alteplase versus systemic anticoagulation alone. Although the effects of thrombolytic therapy for PA pressure reduction have not been specifically investigated, a 2009 study by Kline et al. [21] suggested greater PA pressure reduction and more durable reduction of RV systolic pressure in patients treated with systemic anticoagulation plus bolus alteplase versus systemic anticoagulation alone, although this study was significantly limited by dissimilar sample sizes and disparate study populations. Thus, with limited supporting data, current clinical practice guidelines recommend that application of thrombolysis be reserved for only those submassive PE patients judged to have clinical evidence for an adverse prognosis [7]. In the current study, we investigated the efficacy and safety of flow-directed catheter thrombolysis for treatment of acute submassive PE. In examining the procedure outcomes of 19 patients who underwent targeted thrombolytic therapy, we found that catheter-based fibrinolysis effectively dissolved clot, reestablished PA perfusion, and reduced PA pressure. Complete or near-complete clot dissolution was efficiently achieved 1358 AJR:202, June 2014
5 Catheter Thrombolysis of Submassive PE in 100% of cases, and thrombolysis was associated with near normalization of PA pressures in all cases, with complete normalization of PA pressures in 42% of cases. Low material cost (consisting of standard sheaths, catheters, and guidewires) and simplicity of the flow-directed thrombolytic technique (requiring minimal catheter manipulation) represent additional benefits of the described approach. Most important, 95% of patients in the current series experienced symptomatic improvement and survived to hospital discharge and 90-day follow-up. The results obtained in our study suggest the potential utility of catheter-directed thrombolysis for primary treatment in submassive PE patients, who are at risk of short-term mortality and adverse outcome [10], and our findings may provide a basis for future large-scale prospective multiinstitutional registry or meta-analysis studies comparing catheterdirected thrombolysis outcomes to those of systemic anticoagulation or bolus fibrinolysis, which would be necessary before recommendation for clinical adoption. In the present series, targeted thrombolytic therapy required approximately half the total fibrinolytic agent dose (57 versus 100 mg) compared with that approved by the United States Food and Drug Administration for systemic thrombolysis of massive PE, but we used an off-label manner for treatment of submassive PE, theoretically reducing the risk for hemorrhagic complications. This bleeding risk is further reduced by slow delivery of low-dose alteplase over many hours (mean, 89 hours) compared with 2-hour systemic bolus delivery. Prior studies have confirmed the enhanced safety profile of catheter-directed thrombolytic agent delivery compared with systemic administration, including a nearly 10-fold reduction in major bleeding complications and intracranial hemorrhage [5, 8, 10]. In the sole hemorrhagic complication in the current study, supratherapeutic systemic anticoagulation certainly contributed to adverse event occurrence, whereas normal fibrinogen levels in this case suggested lack of remote lytic effects of alteplase. We thus highlight the need for vigilant anticoagulant management as well as attentive laboratory assessment in patients undergoing thrombolysis. In contrast to the technical approach to targeted therapy for massive PE, which is based on mechanical methods (catheter disruption, balloon fragmentation, and rheolytic thrombectomy) [10] aimed at debulking clot and acutely revascularizing the pulmonary outflow tract to relieve life-threatening heart strain and improve pulmonary perfusion (surgical embolectomy could similarly be used), we support a more conservative approach aimed at slow and steady clot dissolution in the setting of submassive PE. We believe there is no urgent need for acute mechanical thrombus disruption in hemodynamically stable PE patients given the potential to precipitate abrupt hemodynamic deterioration by increasing the cross-sectional area of obstructing embolus, PA pressure, and cardiac afterload [22 24]. In this study, our technical approach to local therapy of submassive PE successfully used flowdirected fibrinolysis without mechanical clot dislodgment and represents a methodology that has been advocated by other authors as well [10]. Notably, ultrasound-accelerated thrombolysis which hastens the penetration of fibrinolytic agent into clot has also been used with safety and efficacy in patients with acute PE [25]. There are limitations to this investigation. First, this study was retrospective and nonrandomized in nature and is subject to the inherent weaknesses of nonprospective studies. Second, our investigation represents the experience of a single institution and has a small sample size accrued without a power analysis to estimate a proper cohort volume. Third, this investigation did not compare outcomes of catheter-directed thrombolysis to those of a control group treated with systemic anticoagulation alone or with systemic fibrinolysis. Fourth, patients were not followed for longterm assessment of RV function or pulmonary hypertension after treatment. In conclusion, flow-directed catheter thrombolysis with low-dose alteplase is effective in dissolving submassive PE and reducing PA pressure and is associated with high rates of survival to hospital discharge as well as 30- and 90-day survival. However, patients undergoing thrombolysis require close observation for bleeding complications. Future studies should aim to collect and analyze prospective data for catheter-directed thrombolysis of submassive PE; further refine treatment protocols by defining optimal treatment approaches on the basis of patient characteristics and clinical circumstances; define favorable catheter-directed techniques that maximize patient safety, effectiveness at clot removal, and ease of use; and compare catheter-directed thrombolysis outcomes to those of systemic anticoagulation and bolus fibrinolysis. References 1. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: Lilienfeld DE, Rubin LJ. Mortality from primary pulmonary hypertension in the United States, Chest 2000; 117: Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e419s 494S 7. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol 2006; 97: Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: Kuo WT. Endovascular therapy for acute pulmonary embolism. J Vasc Interv Radiol 2012; 23: ; quiz, Piazza G, Goldhaber SZ. Acute pulmonary embolism. Part II. Treatment and prophylaxis. Circulation 2006; 114:e42 e Ghaye B, Ghuysen A, Bruyere PJ, D Orio V, Dondelinger RF. Can CT pulmonary angiography allow assessment of severity and prognosis in patients presenting with pulmonary embolism? What the radiologist needs to know. RadioGraphics 2006; 26:23 39; discussion, Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. Management of massive and nonmassive pulmonary embolism. Arch Med Sci 2012; 8: [No authors listed]. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med 1980; 93: Patel NH, Krishnamurthy VN, Kim S, et al. Qual- AJR:202, June
6 Gaba et al. ity improvement guidelines for percutaneous acute pulmonary embolism: the Task Force for the of pulmonary emboli. (letter) Chest 1999; management of acute lower-extremity ischemia. J Diagnosis and Management of Acute Pulmonary 115:1759 Vasc Interv Radiol 2013; 24:3 15 Embolism of the European Society of Cardiology 23. Sanchez O, Trinquart L, Colombet I, et al. Prog- 16. Schmitz-Rode T, Kilbinger M, Gunther RW. Sim- (ESC). Eur Heart J 2008; 29: nostic value of right ventricular dysfunction in ulated flow pattern in massive pulmonary embo- 20. Liu P, Meneveau N, Schiele F, Bassan JP. Predic- patients with haemodynamically stable pulmo- lism: significance for selective intrapulmonary thrombolysis. Cardiovasc Intervent Radiol 1998; 21: Banovac F, Buckley DC, Kuo WT, et al. Reporting standards for endovascular treatment of pulmonary embolism. J Vasc Interv Radiol 2010; 21: Lankeit M, Konstantinides S. Thrombolytic therapy for submassive pulmonary embolism. Best Pract Res Clin Haematol 2012; 25: Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of tors of long-term clinical outcome of patients with acute massive pulmonary embolism after thrombolytic therapy. Chin Med J (Engl) 2003; 116: Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009; 136: Girard P, Simonneau G. Catheter fragmentation nary embolism: a systematic review. Eur Heart J 2008; 29: Nakazawa K, Tajima H, Murata S, Kumita SI, Yamamoto T, Tanaka K. Catheter fragmentation of acute massive pulmonary thromboembolism: distal embolisation and pulmonary arterial pressure elevation. Br J Radiol 2008; 81: Kennedy RJ, Kenney HH, Dunfee BL. Thrombus resolution and hemodynamic recovery using ultrasound-accelerated thrombolysis in acute pulmonary embolism. J Vasc Interv Radiol 2013; 24: AJR:202, June 2014
Management of Massive and Sub-Massive Pulmonary Embolism
Management of Massive and Sub-Massive Pulmonary Embolism M. Montero-Baker, MD L Leon Jr., MD, RVT, FACS Tucson Medical Center Vascular and Endovascular Surgery Section CASE PRESENTATION 54 YEAR- OLD CAUCASIAN
More informationUse of EKOS Catheter in the management of Venous Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group
Use of EKOS Catheter in the management of Venous Thromboembolism @ Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group Introduction Georgia Thrombosis Forum (GTF, www.gtfonline.net)
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Catheter-based thrombolysis Local administration of lytic agent Higher local
More informationWhat is New in Acute Pulmonary Embolism? Interventional Treatment. Prof. Nils Kucher University Hospital Bern Switzerland
What is New in Acute Pulmonary Embolism? Interventional Treatment Prof. Nils Kucher University Hospital Bern Switzerland nils.kucher@insel.ch Disclosure of Interest Dr. Kucher received research grants
More informationVenous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.
Venous Thrombosis Magnitude of the Problem DVT 2 Million Postthrombotic Syndrome 800,000 PE 600,000 Death 60,000 Silent PE 1 Million Pulmonary Hypertension 30,000 Estimated Cost of VTE Care $1.5 Billion/year
More informationEpidemiology of Pulmonary Embolism (PE)
Why Treat Submassive PE Abstract: Massive Pulmonary Embolism (PE) requires immediate lifesaving intervention for the patient. For the submassive PE patient, characterized by presence of right ventricular
More informationDisclosures. Objectives
BRIGHAM AND WOMEN S HOSPITAL Treatment of Massive and Submassive Pulmonary Embolism Gregory Piazza, MD, MS Assistant Professor of Medicine Harvard Medical School Staff Physician, Cardiovascular Division
More informationMassive and Submassive Pulmonary Embolism: 2017 Update and Future Directions
Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions Kush R Desai, MD Assistant Professor of Radiology Northwestern University Feinberg School of Medicine Chicago, IL Disclosures
More informationA 50-year-old woman with syncope
Hira Shahzad 1, Ali Bin Sarwar Zubairi 2 1 Medical College, Aga Khan University Hospital, Karachi 2 Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan Ali Bin Sarwar Zubairi Associate
More informationEpidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment
Update on Pulmonary Embolism Steven M. Dean, DO, FACP, RPVI Program Director- Vascular Medicine Associate Professor of Internal Medicine Division of Cardiovascular Medicine The Ohio State University Keys
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Conflict of Interest BTG Standard PE therapy ANTICOAGULATION (AC) HEPARIN
More informationUltrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism A pulmonary embolism (PE) is
More informationSystemic Fibrinolytic Therapy in the Presence of Absolute Contraindication; a Case Series
Emergency. 2018; 6 (1): e25 CASE REPORT Systemic Fibrinolytic Therapy in the Presence of Absolute Contraindication; a Case Series Mahdi Pishgahi 1, Toktam Alirezaei 1, Behzad Hajimoradi 1, S. Mojtaba Nekooghadam
More informationSingle-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis
Single-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis John A. Phillips, M.D. OhioHealth Heart and Vascular Physicians
More informationInterventional Management of Acute Pulmonary Embolism
Interventional Management of Acute Pulmonary Embolism Prof. Nils Kucher Angiology & Cardiology University Hospital Bern Inselspital nils.kucher@insel.ch DECLARATION OF CONFLICT OF INTEREST Consultant to
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationSurgical Thrombectomy for PE: Is it Making a Comeback
Surgical Thrombectomy for PE: Is it Making a Comeback Prashanth Vallabhajosyula, MD MS The University of Pennsylvania Health System Philadelphia, PA Case - 84 year old female presents with submassive right
More informationSystemic or local thrombolysis in high-risk pulmonary embolism
original article Cardiology Journal 2015, Vol. 22, No. 4, 467 474 DOI: 10.5603/CJ.a2014.0103 Copyright 2015 Via Medica ISSN 1897 5593 Systemic or local thrombolysis in high-risk pulmonary embolism Liviu
More informationAcoustic Pulse Thrombolysis Treatment
Acoustic Pulse Thrombolysis Treatment BTGVascular.com SETTING THE STANDARD FOR VASCULAR THERAPIES Quickly & safely dissolve thrombus with the EKOS System. The Acoustic Pulse Difference Acoustic Pulse Thrombolysis
More informationRadRx Your Prescription for Accurate Coding & Reimbursement Copyright All Rights Reserved.
Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck, RHIA, CCS-P, RCC, CIRCC, AAPC Fellow President & Senior Consultant Week of October 29, 2018 Mesenteric Arteriogram & Thrombectomy/Thrombolysis
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationManagement of Pulmonary Embolism. Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School
Management of Pulmonary Embolism Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School I have no conflicts of interest to report. VTE Overview
More informationCatheter-directed clot fragmentation using the Cleaner TM device in a patient presenting with massive pulmonary embolism
Catheter-directed clot fragmentation using the Cleaner TM device in a patient presenting with massive pulmonary embolism Barjaktarevic I 1, Friedman O 1, Ishak C 2, Sista AK 2* 1. Division of Pulmonary
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence IP1243 Ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism Consultation Comments table IPAC date: Thursday 12 March 2015 1 1 Manufacturer
More informationEmergency Pulmonary Embolectomy after Failed Thrombolysis in a Community Hospital: A Choice of Institutional Preference?
ISPUB.COM The Internet Journal of Emergency Medicine Volume 5 Number 1 Emergency Pulmonary Embolectomy after Failed Thrombolysis in a Community Hospital: A Choice of F Vandy, G Fromm, P Guentert, W Halloran,
More informationEpidemiology: Incidence VTE: Mortality Morbidity Risk Factors: Acute Chronic : Genetic
Submassive PE Pulmonary Embolism Epidemiology: Incidence VTE: 100-200/100,000 = 3rd most frequent cardiovascular disease Symptomatic DVT complicated by PE = 40-50% Sudden fatal PE = 34% Intermediate-risk
More informationSevere pulmonary embolism: Catheter-based thrombolysis and medical treatment
Severe pulmonary embolism: Catheter-based thrombolysis and medical treatment Rolf P. Engelberger, MD Division of Angiology Cantonal Hospital Fribourg & University Hospital Bern, Switzerland Overview Reperfusion
More informationRationale for catheter directed therapy in pulmonary embolism
Mini-Review Rationale for catheter directed therapy in pulmonary embolism Sailen G. Naidu, Martha-Gracia Knuttinen, J. Scott Kriegshauser, William G. Eversman, Rahmi Oklu Department of Radiology, Division
More information4/24/2017 CATHETER-DIRECTED THERAPIES FOR ACUTE PE THE GREY AREA OF SUBMASSIVE PE DISCLOSURES OBJECTIVES: INTRAVASCULAR LYTIC THERAPY
THE GREY AREA OF SUBMASSIVE PE CATHETER-DIRECTED THERAPIES FOR ACUTE PE Submassive PE PE with RV strain Saad Farooqi, MD Pulmonary/Critical Care Fellow Fatal PE Concept borrowed from Jeffrey A. Kline,
More informationRISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain Potential Conflicts of Interest Financial conflicts of
More informationSingle Center 4 year series of 114 consecutive patients treated for massive and submassive PE. Mark Goodwin, MD
Single Center 4 year series of 114 consecutive patients treated for massive and submassive PE Mark Goodwin, MD Disclosure Speaker name:... I have the following potential conflicts of interest to report:
More informationMed Sci Monit, 2016; 22: Grade D. Quality Outstanding
Ain and Jaff. Treatment of Submassive Pulmonary Embolism: Knowing When to be Aggressive and When to be Conservative. Curr Treat Options Cardio Med (2015) 17:25. Review Article Akin et al. Catheter-Directed
More informationInterventional treatment for patients with acute pulmonary embolism
Interventional treatment for patients with acute pulmonary embolism I. Petrov, I. Martinov Cardiology department Tokuda Hospital Sofia I. Petrov, Treatment and prophylaxis of PE Treatment of PE: 1.) Systemic
More informationIs Thrombolysis Only for a Crisis?
Is Thrombolysis Only for a Crisis? December 19, 2017 Is Thrombolysis Only for a Crisis? Indications for Thrombolytic Therapy in Patients with Acute Pulmonary Embolism Case Scenario A 28 year old woman
More informationEKOS. Interventional Vascular 3 February, Imagine where we can go.
EKOS Interventional Vascular 3 February, 2015 Imagine where we can go. Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other
More informationS (18) doi: /j.ajem Reference: YAJEM 57346
Accepted Manuscript A portrait of patients who die in-hospital from acute pulmonary embolism Hesham R. Omar, Mehdi Mirsaeidi, Bishoy Abraham, Garett Enten, Devanand Mangar, Enrico M. Camporesi PII: S0735-6757(18)30172-4
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence IP1219 Ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis Consultation table IPAC date: Thursday 12 March 2015 Com. 1 3 NHS Professional
More informationSachin Kumar Amruthlal Jain, 1 Brijesh Patel, 2 Wadie David, 2 Ayad Jazrawi, 1 and Patrick Alexander Introduction
Hindawi Publishing Corporation Case Reports in Medicine Volume 2014, Article ID 297951, 8 pages http://dx.doi.org/10.1155/2014/297951 Case Report Unloading of Right Ventricle and Clinical Improvement after
More informationInterventional Treatment VTE: Radiologic Approach
Interventional Treatment VTE: Radiologic Approach Hae Giu Lee, MD Professor, Dept of Radiology Seoul St. Mary s Hospital The Catholic University of Korea Introduction Incidence High incidence: 250,000-1,000,000/year
More informationRadRx Your Prescription for Accurate Coding & Reimbursement Copyright All Rights Reserved.
Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck, RHIA, CCS-P, RCC, CIRCC, AAPC Fellow President & Senior Consultant Week of June 4, 2018 Thrombolysis, Thrombectomy & Angioplasty
More informationPulmonary Embolectomy:
Pulmonary Embolectomy: Recommendation for early surgical intervention Tomas A. Salerno, M.D. Professor of Surgery, University of Miami Miller School of Medicine and Jackson Memorial Hospital Epidemiology
More informationCatheter-directed Thrombolysis for Pulmonary Embolism
Catheter-directed Thrombolysis for Pulmonary Embolism Is It Good Advice to Lyse? Texas Society of Health-System Pharmacists April 7, 2018 Rebecca L. Attridge, PharmD, MSc, BCPS Associate Professor, University
More informationMark H. Meissner, MD Peter Gloviczki Professor of Venous & Lymphatic Disorders University of Washington School of Medicine
Pulmonary Embolism Response Teams Not So Fast Early Interventions is a House of Cards Mark H. Meissner, MD Peter Gloviczki Professor of Venous & Lymphatic Disorders University of Washington School of Medicine
More informationThrombolysis in PE. Outline. Disclosure. Overview on Pulmonary Embolism. Hot Topics in Emergency Medicine 2012 Midyear Clinical Meeting
Disclosure Thrombolysis in PE Daniel P. Hays, PharmD, BCPS, FASHP reports no relevant financial relationships. Daniel P. Hays, PharmD, BCPS, FASHP Outline 55 YOF presents to ED with SOB PMH of DVT + noncompliance
More informationΜακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή
Μακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή Ευφροσύνη Δ. Μάναλη Λέκτορας Β Πανεπιστημιακή Πνευμονολογική Κλινική ΓΝΑ «Αττικόν» Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών Existing guidelines
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationCatheter-Directed Thrombolysis for Acute Limb Ischemia. Hwan Jun Jae MD Seoul National University Hospital Seoul, Korea
Catheter-Directed Thrombolysis for Acute Limb Ischemia Hwan Jun Jae MD Seoul National University Hospital Seoul, Korea Disclosure Speaker name: Hwan Jun Jae... I have the following potential conflicts
More informationDepartment of Anaesthesiology and Intensive Care Unit, Jagiellonian University Medical College, University Hospital, Krakow, Poland
Original paper Vascular surgery Videosurgery Treatment of high- and intermediate-risk pulmonary embolism using the AngioJet percutaneous mechanical thrombectomy system in patients with contraindications
More informationRyan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center
Ryan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center The opinions expressed herein are solely those of the author and do not represent the official views of the Department of Defense
More informationGuideline for Thrombolysis Therapy in Pulmonary Embolism
Guideline for Thrombolysis Therapy in Pulmonary Embolism Dr Jane Strong Consultant Haematologist Trust ref: B24/2016 1. Introduction / Scope All Patients with pulmonary embolism (PE) require rapid risk
More informationCatheter Directed Interventions for Pulmonary Embolism
Catheter Directed Interventions for Pulmonary Embolism Rabih A. Chaer, MD, MSc Professor of Surgery, UPMC Residency Program Director Site chief, Presbyterian campus Division of Vascular Surgery Pittsburgh,
More informationManagement of Acute Pulmonary Embolism. Judith Hurdman Consultant Respiratory Physician
Management of Acute Pulmonary Embolism Judith Hurdman Consultant Respiratory Physician Judith.hurdman@sth.nhs.uk Overview Risk Stratification Who can be managed as an outpatient? To thrombolyse or not
More informationCase. Case. Management of Pulmonary Embolism in the ICU
Management of Pulmonary Embolism in the ICU Todd M Bull, M.D. Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationORIGINAL INVESTIGATION. Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism
Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism A Clinical Outcome Based Meta-analysis ORIGINAL INVESTIGATION Giancarlo Agnelli, MD; Cecilia Becattini, MD; Timo Kirschstein, MD Background:
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Prognostic Role of Echocardiography Among Patients With Acute Pulmonary Embolism and a Systolic Arterial Pressure of 90 mm Hg or Higher Nils Kucher, MD; Elisa Rossi, BS; Marisa De
More informationCatheter Interventions for pulmonary embolism:
Catheter Interventions for pulmonary embolism: From Directed tpa Drips to Suction Thrombectomy Efthymios Avgerinos, MD Associate Professor of Surgery Division of Vascular Surgery University of Pittsburgh
More informationCase Report Free Floating Right Heart Thrombus Associated with Acute Pulmonary Embolism: An Unsettled Therapeutic Difficulty
Case Reports in Cardiology Volume 2015, Article ID 364780, 4 pages http://dx.doi.org/10.1155/2015/364780 Case Report Free Floating Right Heart Thrombus Associated with Acute Pulmonary Embolism: An Unsettled
More informationENDOVASCULAR THERAPIES FOR ACUTE STROKE
ENDOVASCULAR THERAPIES FOR ACUTE STROKE Cerebral Arteriogram Cerebral Anatomy Cerebral Anatomy Brain Imaging Acute Ischemic Stroke (AIS) Therapy Main goal is to restore blood flow and improve perfusion
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST IDENTIFYING LOW-RISK PULMONARY EMBOLISM CLINICAL SCORES David Jiménez, MD, PhD Respiratory Department Ramón y Cajal Hospital Madrid, Spain Potential Conflicts of Interest
More informationPulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT) Initial Results From a Prospective Multicenter Registry
[ Original Research Pulmonary Vascular Disease ] Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT) Initial Results From a Prospective Multicenter Registry William
More informationIntervention for Deep Venous Thrombosis and Pulmonary Embolus
Intervention for Deep Venous Thrombosis and Pulmonary Embolus Michael R. Jaff, DO Paul and Phyllis Fireman Endowed Chair in Vascular Medicine Massachusetts General Hospital Professor of Medicine Harvard
More informationTemporary Pulmonary Stent Placement as Emergency Treatment of Pulmonary Embolism First Experimental Evaluation
Journal of the American College of Cardiology Vol. 48, No. 4, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.079
More informationAcute Pulmonary Embolism and Deep Vein Thrombosis. Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center COPYRIGHT
Acute Pulmonary Embolism and Deep Vein Thrombosis Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center Acute PE and DVT No disclosures. Acute PE and DVT Learning objectives
More informationPULMONARY EMBOLISM -CASE REPORT-
University Goce Delcev, Faculty of Medical sciences, Stip University Clinic of Cardiology, Skopje R. Of Macedonia PULMONARY EMBOLISM -CASE REPORT- Gordana Kamceva MD mr.sci Acknowledgment Marija Vavlukis
More informationPercutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience
JFICV 2018, Beaune Percutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience Prof. Romaric LOFFROY, MD, PhD, FCIRSE Chief, Department of Vascular and
More informationOutcomes Of Combined Rheolytic And Rotational Mechanical Thrombectomy For Total Access Circuit Thrombosis In Hemodialysis Patients
Outcomes Of Combined Rheolytic And Rotational Mechanical Thrombectomy For Total Access Circuit Thrombosis In Hemodialysis Patients Nicholas Petruzzi, MD Raphael Cohen, MD Mark Mantell, MD Timothy W. Clark,
More informationRisk-Based Evaluation and Management of VTE
12:50-1:50pm Risk-Based Evaluation and Management of VTE SPEAKER Gregory Piazza, MD, MS BRIGHAM AND WOMEN S HOSPITAL Risk-Based Evaluation and Management of VTE Gregory Piazza, MD, MS Assistant Professor
More informationModified Wells criteria
Venous Thromboembolic Disease Jessica Weber, D.O. Diagnostic Imaging Associates, Oklahoma State University Medical Center, Tulsa, OK Introduction Venous thromboembolic disease is a major cause of morbidity
More informationEffectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K Record Status This is a critical abstract of an economic evaluation that meets
More informationPulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
More informationAcute Management of Pulmonary Embolism
Acute Management of Pulmonary Embolism Dr Alex West Respiratory Consultant Guy s and St Thomas Hospital London Declarations - none Order of Play Up date in Diagnostic Imaging - CTPA and V:Q SPECT Sub-massive
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationA Comparison of the Effectiveness of Dual Catheter and Embedded Catheter Techniques used for PE Thrombolysis
A Comparison of the Effectiveness of Dual Catheter and Embedded Catheter Techniques used for PE Thrombolysis Candace Hughes Radiologic Technology Presented in Partial Fulfillment of the Requirements for
More information1 Description. 2 Indications. 3 Warnings ASPIRATION CATHETER
Page 1 of 5 ASPIRATION CATHETER Carefully read all instructions prior to use, observe all warnings and precautions noted throughout these instructions. Failure to do so may result in complications. STERILE.
More informationThe principal criterion to characterize acute pulmonary
Vascular Medicine Massive ulmonary Embolism Nils Kucher, MD; Elisa Rossi, BS; Marisa De Rosa, hd; Samuel Z. Goldhaber, MD Background Acute massive pulmonary embolism (E) carries an exceptionally high mortality
More informationSurgical approach for DVT. Division of Vascular Surgery Department of Surgery Seoul National University College of Medicine
Surgical approach for DVT Seung-Kee Min Division of Vascular Surgery Department of Surgery Seoul National University College of Medicine Treatment Options for Venous Thrombosis Unfractionated heparin &
More informationTom Eisele, Benedikt M. Muenz, and Grigorios Korosoglou. Department of Cardiology & Vascular Medicine, GRN Hospital Weinheim, Weinheim, Germany
Case Reports in Vascular Medicine Volume 2016, Article ID 7376457, 4 pages http://dx.doi.org/10.1155/2016/7376457 Case Report Successful Endovascular Repair of an Iatrogenic Perforation of the Superficial
More informationOptimal Utilization of Thrombolytics
April 8-9, 2011 New York LaGuardia Marriott COMPLETE MANAGEMENT OF VENOUS DISEASE Optimal Utilization of Thrombolytics Anthony J. Comerota, MD, FACS, FACC Director, Jobst Vascular Institute Adjunct Professor
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationClinical Practice Statement. What is the Role of Thrombolysis in Intermediate Risk Pulmonary Embolism?
Clinical Practice Statement What is the Role of Thrombolysis in Intermediate Risk Pulmonary Embolism? Co-Chairs: Authors: Steve Rosenbaum, MD FAAEM Michael Abraham, MD FAAEM David Pillus, MD FAAEM Eric
More informationPE is a difficult diagnosis that may be missed because of non-specific clinical presentation.
Pulmonary embolism (PE) is a relatively common cardiovascular emergency. By occluding the pulmonary arterial bed it may lead to acute life-threatening (3% early mortality rate), but potentially reversible
More informationPercutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related. Iliocaval Thrombosis
Percutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related Iliocaval Thrombosis Faiz D. Francis, DO; Gianvito Salerno, MD; Sabbah D. Butty, MD Abstract In the setting of
More informationManagement of Acute Pulmonary Embolism: Anticipating and Responding to Complexity Ahmed Zaky, M.D., M.P.H. University of Alabama, Birmingham, AL
Session: L213 Session: L403 Management of Acute Pulmonary Embolism: Anticipating and Responding to Complexity Ahmed Zaky, M.D., M.P.H. University of Alabama, Birmingham, AL Disclosures: This presenter
More informationRECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS.
DRAFT-2018 UPDATES RECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS. Target Audience: MultiCare physicians managing adult patients with massive and submassive
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationCARDIAC PROBLEMS IN PREGNANCY
CARDIAC PROBLEMS IN PREGNANCY LAS VEGAS, NEVADA, USA 27 February 1 March 2016 SUCCESSFUL TREATMENT WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR OF MASSIVE PULMONARY EMBOLISM IN THE 16 TH WEEK OF PREGNANCY
More informationOctober 2017 Pulmonary Embolism
October 2017 Pulmonary Embolism Prof. Ahmed BaHammam, FRCP, FCCP Professor of Medicine College of Medicine King Saud University 1 Objectives Epidemiology Pathophysiology Diagnosis Massive PE Treatment
More informationThrombus Removal in Acute Pulmonary Embolism: When and How?
Thrombus Removal in Acute Pulmonary Embolism: When and How? Kenneth Rosenfield, MD, MHCDS, MSCAI Cardiology Division Section of Vascular Medicine and Intvn MGH Kenneth Rosenfield, MD, MHCDS Conflicts of
More informationPulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical
Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases
More informationPulmonary Embolism. Thoracic radiologist Helena Lauri
Pulmonary Embolism Thoracic radiologist Helena Lauri 8.5.2017 Statistics 1-2 out of 1000 adults annually are diagnosed with deep vein thrombosis (DVT) and/or pulmonary embolism (PE) About half of patients
More informationThe OPTALYSE PE Trial Reducing thrombolytic dose and treatment times with EKOS in the treatment of pulmonary embolism patients
The OPTALYSE PE Trial Reducing thrombolytic dose and treatment times with EKOS in the treatment of pulmonary embolism patients Keith M. Sterling, M.D. Director, Cardiovascular & Interventional Radiology
More informationTreatment of pulmonary thromboembolism using Arrow-Trerotola percutaneous thrombolytic device
CASE REPORT pissn 1225-7737/eISSN 2234-8042 Yeungnam Univ J Med 2014;31(1):28-32 http://dx.doi.org/10.12701/yujm.2014.31.1.28 Treatment of pulmonary thromboembolism using Arrow-Trerotola percutaneous thrombolytic
More informationACUTE PULMONARY EMBOLISM MIMICS ACUTE CORONARY SYNDROME IN OLDER PATIENT
CASE REPORT ACUTE PULMONARY EMBOLISM MIMICS ACUTE CORONARY SYNDROME IN OLDER PATIENT Chun-Chieh Liu 1,2 *, Ta-Chuan Hung 1,2, Charles Jia-Yin Hou 1,2, Cheng-Ho Tsai 1,2,3 1 Cardiovascular Medicine, Department
More informationPrognostic value of the ECG on admission in patients with acute major pulmonary embolism
Eur Respir J 2005; 25: 843 848 DOI: 10.1183/09031936.05.00119704 CopyrightßERS Journals Ltd 2005 Prognostic value of the ECG on admission in patients with acute major pulmonary embolism A. Geibel*, M.
More informationRECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS.
RECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS. Target Audience: Physicians managing adult patients with massive and submassive pulmonary emboli in the
More informationMassive Pulmonary Embolism: Percutaneous Mechanical Thrombectomy during Cardiopulmonary Resuscitation
Massive Pulmonary Embolism: Percutaneous Mechanical Thrombectomy during Cardiopulmonary Resuscitation Mario Fava, MD, Soledad Loyola, MD, Hernán Bertoni, MD, and Alberto Dougnac, MD Seven patients with
More informationThe hallmark of percutaneous thrombus management
Treating Venous Thromboembolism Without Lytic Medications What the present and the near future will bring in terms of techniques and devices to remove venous thrombus. BY CONSTANTINO S. PEÑA, MD; RIPAL
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More information